Login / Signup

In Vitro and In Vivo Sequestration of Phencyclidine by Me4 Cucurbit[8]uril*.

Steven MurkliJared KlemmAdam T BrockettMichael ShusterVolker BrikenMatthew R RoeschLyle D Isaacs
Published in: Chemistry (Weinheim an der Bergstrasse, Germany) (2021)
We report investigations of the use of cucurbit[8]uril (CB[8]) macrocycles as an antidote to counteract the in vivo biological effects of phencyclidine. We investigate the binding of CB[8] and its derivative Me4 CB[8] toward ten drugs of abuse (3-9, 12-14) by a combination of 1 H NMR spectroscopy and isothermal titration calorimetry in phosphate buffered water. We find that the cavity of CB[8] and Me4 CB[8] are able to encapsulate the 1-amino-1-aryl-cyclohexane ring system of phencyclidine (PCP) and ketamine as well as the morphinan skeleton of morphine and hydromorphone with Kd values ≤50 nm. In vitro cytotoxicity (MTS metabolic and adenylate kinase cell death assays in HEK293 and HEPG2 cells) and in vivo maximum tolerated dose studies (Swiss Webster mice) which were performed for Me4 CB[8] indicated good tolerability. The tightest host⋅guest pair (Me4 CB[8]⋅PCP; Kd =2 nm) was advanced to in vivo efficacy studies. The results of open field tests demonstrate that pretreatment of mice with Me4 CB[8] prevents subsequent hyperlocomotion induction by PCP and also that treatment of animals previously dosed with PCP with Me4 CB[8] significantly reduces the locomotion levels.
Keyphrases
  • cell death
  • type diabetes
  • minimally invasive
  • metabolic syndrome
  • clinical trial
  • skeletal muscle
  • adipose tissue
  • wild type
  • single cell
  • protein kinase
  • combination therapy
  • dna binding